Anthropic has established a wet laboratory in the San Francisco Bay Area as part of its growing life sciences efforts, moving beyond computer-based biological analysis and into physical laboratory research, according to two people familiar with the matter and comments from company executives.
The artificial intelligence startup has said it wants to help unlock treatments for rare diseases, and its biology work has expanded beyond in silico, or computer-based, evaluations. In an interview with Reuters, Eric Kauderer-Abrams, Anthropic’s head of life sciences, confirmed that the company is conducting laboratory research.
“We believe that to do biology, the final test is still and will be for a while in real lab work,” Kauderer-Abrams said.
A company spokesperson later clarified that the laboratory is not specifically for drug discovery and declined to provide further details.
Laboratory Work Expands Beyond Digital Research
According to two people familiar with the matter, Anthropic has adopted physical automation technologies as part of its biology efforts.
One focus is exploring how its Claude AI system can direct robotic units to conduct scientific experiments with limited human intervention. However, the company said human oversight and involvement remain essential for safety.
Kauderer-Abrams said the use of AI to automate laboratory execution remains in its early stages but has the potential to accelerate many processes.
The effort also has personal significance for Anthropic Chief Executive Officer Dario Amodei. In a recent essay, he said his father died from a disease only a few years before a cure became available. Kauderer-Abrams said the company sees its largest opportunity to benefit the world through life sciences work.
Expansion of Internal Life Sciences Capabilities
Anthropic publicly outlined its intention to run drug programs during an event in San Francisco in June. At the event, Kauderer-Abrams said the company planned to conduct preclinical work in areas that traditional companies did not find financially attractive.
The company has also launched software called Claude Science, added Novartis CEO Vas Narasimhan to its board, and acquired startup Coefficient Bio. Anthropic confirmed the acquisition and said it would help the company build tools for drug development, though it declined to comment on reported deal terms.
Kauderer-Abrams told Reuters that Anthropic is increasing its in-house laboratory efforts for speed and for firsthand experience in biology, while continuing to outsource work when it is more efficient to do so.
Recent hiring activity reflects those plans. One LinkedIn posting sought a leader to expand procurement and other operations, while another position advertised through Jobera looked for expertise in protein and nucleic acid characterization and related biochemical work. A separate job listing stated that Anthropic’s goal is to speed progress in the life sciences by an order of magnitude.
According to Kauderer-Abrams, life sciences already represents one of Anthropic’s largest investment areas in terms of personnel and resources.
Focus on Difficult Biological Challenges
Kauderer-Abrams said AI could accelerate development for conditions previously considered “undruggable.” He pointed to the potential for faster discovery of bispecific and trispecific antibodies, which can target multiple points on a protein or cell or act on multiple targets.
The specific diseases Anthropic is pursuing, and the progress of those efforts, have not been disclosed. The company is also not conducting clinical trials and has said it is focusing on needs that industry does not address.
In August, Anthropic introduced the Model Hardware Standard, which helps AI systems operate laboratory equipment. The company also provides AI services and tools to pharmaceutical companies including Roche’s Genentech, Bristol Myers Squibb and Novo Nordisk.
At the same time, Anthropic is managing concerns from customers that it could gain insight into competing drug-development programs, despite keeping customer data separated. Kauderer-Abrams said Anthropic has drawn a boundary around its activities and is not running clinical trials, partly because of competition concerns.
He said the company is not competing with pharmaceutical and biotechnology firms whose business is bringing drugs to market.
Anthropic has confirmed that it operates a wet biology laboratory in the San Francisco Bay Area, marking an expansion of its efforts to apply artificial intelligence to life sciences and physical biological research. The facility allows the company to move beyond computer-based experiments and conduct work in a real laboratory environment.
The development represents a significant step in Anthropic’s growing life-sciences strategy. According to reporting from Reuters and TechCrunch, the company is combining AI capabilities with laboratory research while also working with external partners. Anthropic’s head of life sciences, Eric Kauderer-Abrams, said real laboratory work remains an important test for biological research.
Anthropic Brings AI Research Into the Physical Lab
The Anthropic wet lab gives researchers an environment where biological ideas generated or supported by AI can be tested through physical experiments. This creates a connection between computational models and real-world biological data.
Anthropic’s Growing Life Sciences Strategy
The new facility is part of a broader Anthropic push into life sciences. The company has been developing tools and partnerships aimed at applying advanced AI systems to scientific research, including biology and drug-development-related work. Its acquisition of Coefficient Bio has also contributed to its expanding capabilities in the field.
For the pharmaceutical and biotechnology sectors, Anthropic’s move highlights the increasing role of AI in experimental biology. Physical laboratory testing can provide data that complements computational predictions, potentially creating new workflows for researchers working on complex biological questions.
What Anthropic’s Wet Lab Means for AI and Biology
Anthropic’s Bay Area laboratory demonstrates how AI companies are increasingly moving from purely digital research toward systems that interact with physical scientific environments. The combination of AI models, laboratory automation and biological experimentation could become an important area of development across life sciences.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
